Find Lutetium-177 Vipivotide Tetraxetan manufacturers, exporters & distributors on PharmaCompass

177 Lu-Labeled Psma-617

177 Lu-Labeled Psma-617

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 API Suppliers, 1 USDMF, 2 NDC API

DEVELOPMENTS

17 Drug(s) in Development

17 Drug(s) in Development

DOSSIERs // Finished Dosage Formulations

2 Dossiers, 1 FDA Orange Book, 1 Canada

PATENTS

3 US Patents, 1 US Exclusivities

DIGITAL CONTENT

24 News, 2 Monthly Stock Recap #PipelineProspector

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 177lu-psma-617, G6uf363ecx, Vipivotide tetraxetan lu-177, 177lu-labeled psma-617, Lutetium lu-177 vipivotide tetraxetan, Vipivotide tetraxetan lutetium lu-177

Molecular Formula

C₄₉H₆₈LuN₉O₁₆

Molecular Weight

1216.1 g/mol

InChI Key

RSTDSVVLNYFDHY-IOCOTODDSA-K

FDA UNII

G6UF363ECX

Lutetium Lu 177 Vipivotide Tetraxetan is a radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.

1 2D Structure

177 Lu-Labeled Psma-617

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[4-[2-[[4-[[(2S)-1-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]cyclohexyl]methylamino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)

2.1.2 InChI

InChI=1S/C49H71N9O16.Lu/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61;/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74);/q;+3/p-3/t32?,35?,37-,38-,39-;/m0./s1/i;1+2

2.1.3 InChI Key

RSTDSVVLNYFDHY-IOCOTODDSA-K

2.1.4 Canonical SMILES

C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O.[Lu+3]

2.1.5 Isomeric SMILES

C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O.[177Lu+3]

2.2 Other Identifiers

2.2.1 UNII

G6UF363ECX

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 177lu-617-prostate-specific Membrane Antigen Ligand

2. 177lu-psma-617

2.3.2 Depositor-Supplied Synonyms

1. 177lu-psma-617

2. G6uf363ecx

3. Vipivotide Tetraxetan Lu-177

4. 177lu-labeled Psma-617

5. Lutetium Lu-177 Vipivotide Tetraxetan

6. Vipivotide Tetraxetan Lutetium Lu-177

7. Lutetium (177lu) Vipivotide Tetraxetan

8. Lutetium (177lu) Vipivotide Tetraxetan [inn]

9. Lutetium Lu 177 Vipivotide Tetraxetan [usan]

10. Pluvicto

11. Unii-g6uf363ecx

12. Who 11429

13. Lutetium (177lu) Vipivotide Tetraxetan [who-dd]

14. 1703749-62-5

15. 1983157-55-6

16. Lutetate(3-)-177lu, (n-((((1s)-1-carboxy-5-(((2s)-3-(2-naphthalenyl)-1-oxo-2-(((trans-4-(((2-(4,7,10-tris((carboxy-.kappa.o)methyl)-1,4,7,10-tetraazacyclododec-1-yl-.kappa.n1,.kappa.n4,.kappa.n7,.kappa.n10)acetyl-.kappa.o)amino)methyl)cyclohexyl)carbonyl)amino)propyl)amino)pentyl)amino)carbonyl)-l-glutamato(6-))-, Hydrogen (1:3)

17. Lutetate(3-)-177lu, (n2-((((1s)-1,3-dicarboxypropyl)amino)carbonyl)-n6-(3-(2-naphthalenyl)-n-((trans-4-(((2-(4,7,10-tris((carboxy-.kappa.o)methyl)-1,4,7,10-tetraazacyclododec-1-yl-.kappa.n1,.kappa.n4,.kappa.n7,.kappa.n10)acetyl-.kappa.o)amino)methyl)cyclohexyl)carbonyl)-l-alanyl)-l-lysinato(6-))-, Hydrogen (1:3

2.4 Create Date

2016-12-16

3 Chemical and Physical Properties

Molecular Formula	C₄₉H₆₈LuN₉O₁₆
Molecular Weight	1216.1 g/mol
Hydrogen Bond Donor Count	8
Hydrogen Bond Acceptor Count	20
Rotatable Bond Count	24
Exact Mass	1215.42217 g/mol
Monoisotopic Mass	1215.42217 g/mol
Topological Polar Surface Area	374 Å²
Heavy Atom Count	75
Formal Charge	0
Complexity	1860
Isotope Atom Count	1
Defined Atom Stereocenter Count	3
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Treatment of PSMA-expressing prostate cancer

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Radiopharmaceuticals

Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)